In this regard, preclinical data from our group support the notion that combinational immunotherapy with anti-CD20 and anti-PD-1 can reinvigorate T cells and anti-tumour specificity, improving long-term overall survival in animal models of PD-L1-positive DLBCL [133]. Here, CD274 is linked to diffuse large B-cell lymphoma.